



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Koselugo

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency's update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to **EPAR - Procedural steps taken and scientific information after authorisation (archive)**.

Application number	Scope	Opinion/ Notification ¹ issued on	Commission Decision Issued ² / amended on	Product Information affected ³	Summary
Variation type II /	C.I.6 Change(s) to therapeutic indication(s)	18/09/2025	24/10/2025	SmPC and PL	Please refer to Scientific Discussion Koselugo-II-

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



EMA/VR/0000245231	<p>- C.I.6.a Addition of a new therapeutic indication or modification of an approved one</p> <p>- Accepted</p> <p>Extension of indication for KOSELUGO to include treatment of adults based on results from study D134BC00001 (KOMET). This is a phase III, multicentre, international study with a parallel, randomised, double-blind, placebo-controlled, 2 arm design that assesses efficacy and safety of selumetinib in adult participants with NF1 who have Symptomatic Inoperable Plexiform Neurofibromas. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 4.1 of the RMP has also been agreed. In addition, the Marketing authorisation holder (MAH) took the opportunity to implement editorial changes to the SmPC.</p>				EMAVR0000245231-AR-en.
PSUR / EMA/PSUR/0000282270	- -				Maintenance